Small animal PET in oncology: The road from bench to bedside

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 2, 2009, Pages 277-285

  Ambrosini, Valentina ^a   Quarta, Carmelo ^a   Nanni, Cristina ^a   Pettinato, Cinzia ^a   Franchi, Roberto ^a   Grassetto, Gaia ^b   Al Nahhas, Adil ^c   Fanti, Stefano ^a   Rubello, Domenico ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b S MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Molecular imaging; Small animal PET; Tumor biology

Indexed keywords

(5 DIMETHYLAMINO) 1 NAPTHTHALENESULFONYL ALPHA ETHYL FLUOROALANINE; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID CU 64; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID EPIDERMAL GROWTH FACTOR GA 68; 3' FLUOROTHYMIDINE F 18; 6 FLUORODOPA F 18; ARGINYLGLYCYLASPARTIC ACID; BEVACIZUMAB; BUT 2 ENEDIOIC ACID [4 (3 IODOANILINO)QUINAZOLIN 6 YL]AMIDE(3 MORPHOLIN 4 YL PROPYL)AMIDE I 124; CELL RECEPTOR; CHOLINE C 11; CHOLINE F 18; CLEVUDINE F 18; FLUOROACETIC ACID F 18; FLUORODEOXYGLUCOSE F 18; FLUOROESTRADIOL F 18; GALLIUM 68; GEFITINIB F 18; NST 732; STREPTAVIDIN CU 64; TRACER; UNCLASSIFIED DRUG; VASCULOTROPIN; VITRONECTIN RECEPTOR;

ANGIOGENESIS; APOPTOSIS; BONE METASTASIS; CANCER DIAGNOSIS; CELL PROLIFERATION; DRUG HALF LIFE; DRUG UPTAKE; IMAGE RECONSTRUCTION; METABOLISM; NEUROBLASTOMA; NONHUMAN; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; RHABDOMYOSARCOMA; TUMOR CELL; TUMOR XENOGRAFT;

ANIMALS; HUMANS; MODELS, ANIMAL; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY;

EID: 66249100885     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0554     Document Type: Review

References (98)

1. Pantaleo MA, Nannini M, Maleddu A, et al. Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. Cancer Treat Revi 2008; 34: 103.
2. Hutchings M, Specht L. PET/CT in the management of haematological malignancies. Eur J Haematol 2008; 80: 369.
3. Stauss J, Franzius C, Pfluger T, et al. Guidelines for (18) F- FDG PET and PET-CT imaging in paediatric oncology. Eur J Nucl Med Mol Imaging 2008 Jun. 7 [Epub ahead of print].
4. Coleman RE. Value of FDG-PET scanning in management of lung cancer. Lancet 2002; 359: 1361.
5. Boss DS, Olmos RV, Sinaasappel M, et al. Application of PET/CT in the development of novel anticancer drugs. Oncologist 2008; 13: 25.
6. 18F- DOPA PET/CT imaging in the management of patients with 111ln-pentreotide negative GEP tumors. Nucl Med Communi 2007; 28: 473. (Pubitemid 46684197)
7. Malakoff D. The rise of the mouse, biomedicine's model mammal. Science 2000; 288: 248. (Pubitemid 30226172)
8. Bloomfield PM, Rajeswaran S, Spinks TJ, et al. The design and physical characteristics of a small animal positron emission tomograph. Phys Med Biol 1995; 40: 1105.
9. Cherry SR, Shao Y, Silverman RW, et al. MicroPET: A high resolution PET scanner for imaging small animals. IEEE Transact Nucl Sci 1997; 44: 1161. (Pubitemid 127827067)
10. Seidel J, Vaquero JJ, Green MV. Resolution uniformity and sensitivity of the NIH ATLAS small animal PET scanner: Comparison to simulated LSO scanners without depthof-interaction capability. IEEE Transact Nucl Sci 2003; 80: 1347.
11. Huisman MC, Reder S, Weber AW, et al. Performance evaluation of the Philips MOSAIC small animal PET scanner. Eur J Nucl Med Mol Imaging 2007; 34: 532. (Pubitemid 46426995)
12. Tai YC, Ruangma A, Rowland D, et al. Performance evaluation of the microPET focus: A third-generation microPET scanner dedicated to animal imaging. J Nucl Med 2005; 46: 455. (Pubitemid 43093155)
13. Wang Y, Seidel J, Tsui BM, et al. Performance evaluation of the GE healthcare eXplore VISTA dual-ring small-animal PET scanner. J Nucl Med 2006; 47: 1891. (Pubitemid 47545013)
14. Daube-Witherspoon ME, Matej S, Karp JS, et al. A rowaction alternative to the EM algorithm for maximizing likelihoods in emission tomography. IEEE Trans Nucl Sci 2001; 48: 24.
15. Defrise M, Kinahan PE, Townsend DW, et al. Exact and approximate rebinning algorithms for 3-D PET data. IEEE Trans Med Imaging 1997; 16: 145. (Pubitemid 127762926)
16. Sossiand V, Ruth J. Micropet imaging: In vivo biochemistry in small animals. J Neur Transm 2005; 112: 319. (Pubitemid 40868047)
17. Massoud TF, Gambhir SS. Molecular imaging in living subjects: Seeing fundamental biological processes in a new light. Genes Devel 2003; 17: 545. (Pubitemid 36307540)
18. 18F- FDG microPET studies in mouse tumor xenografts. J Nucl Med 2007; 48: 602. (Pubitemid 47571417)
19. Tseng JR, Dandekar M, Subbarayan M, et al. Reproducibility of 3' -deoxy-3'- (18) F-fluorothymidine microPET studies in tumor xenografts in mice. J Nucl Med 2005; 46: 1851. (Pubitemid 46196647)
20. Abbey CK, Borowsky AD, McGoldrick ET, et al. In vivo positron emission tomography imaging of progression and transformation in a mouse model of mammary neoplasia. Proc Natl Acad Sci U S A 2004; 101: 11438. (Pubitemid 39038365)
21. 18F]fluoroethyl) - L-tyrosine (FET) : A tracer for differentiation of tumour from inflammation in murine lymph nodes. Eur J Nucl Med Mol Imaging. 2002; 29: 1039. (Pubitemid 44298186)
22. Lindholm P, Minn H, Leskinen-Kallio S, et al. Influence of the blood glucose concentration on FDG uptake in cancer: A PET study. J Nucl Med 1993; 34: 1. (Pubitemid 23014212)
23. 18-FDG: Society of Nuclear Medicine. J Nucl Med 1998; 39: 1302.
24. 18F]FDG uptake in mouse brain and heart using small animal PET. Nucl Med Biol 2004; 31: 251. (Pubitemid 38315120)
25. Rowland DJ, Cherry SR. Small-animal preclinical nuclear medicine instrumentation and methodology. Semin Nucl Med 2008; 38: 209.
26. Nanni C, Pettinato C, Ambrosini V, et al. Retro-orbital injection is an effective route for radiopharmaceutical administration in mice during small-animal PET studies. Nucl Med Communi 2007; 28: 547. (Pubitemid 46848647)
27. 18F-FDG PET studies in mice. J Nucl Med 2006; 47: 999. (Pubitemid 46939953)
28. 18F-FDG PET/CT. J Nucl Med 2003; 44: 1267. (Pubitemid 39655187)
29. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 2008; 49 (Suppl 2) : 24S.
30. Krebs HA. The Pasteur effect and the relations between respiration and fermentation. Ass Biochemi 1972; 8: 1.
31. Racker E, Wu R. Limiting factors in glycolysis of ascites tumour cells and the pasteur effect. Reg Cell Metab 1958; 205.
32. Wu R, Racker E. Regulatory mechanisms in carbohydrate metabolism. IV. Pasteur effect and crabtree effect in ascites tumor cells. J Biol Chemi 1959; 234: 1036.
33. Hanahan D, Weinberg RA. The hallmarks of cancer. Cells 2000; 100: 57. (Pubitemid 30046295)
34. Nanni C, Di Leo K, Tonelli R, et al. FDG small animal PET permits early detection of malignant cells in a xenograft murine model. Eur J Nucl Med Mol Imaging 2007; 34: 755. (Pubitemid 46669360)
35. 18F-FDG small animal PET for early detection of human anaplastic large cells lymphoma xenograft in immunocompromised mice. Anticancer Res 2008; 28: 981.
36. 18F-FDG small-animal PET. J Nucl Med 2008; 49: 129.
37. Chaise C, Itti E, Petegnief Y, Wirquin E, et al. [F-p18]-Fluoro- 2-deoxy-D:-glucose positron emission tomography as a tool for early detection of immunotherapy response in a murine B cell lymphoma model. Cancer Immunol Immunother 2007; 56: 1163. (Pubitemid 46763931)
38. Shields AF, Grierson JR, Dohmen BM. Imaging proliferation in vivo with F-18-FLT and positron emission tomoghraphy. Nat Med 1998; 1334. (Pubitemid 28512118)
39. Rasey JS, Grierson JR, Wiens LW, et al. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002; 43: 1210.
40. 18FDG. J Nucl Med 2003; 44: 1426. (Pubitemid 39663355)
41. Vesselle H, Grierson J, Muzi M, et al. In vivo validation of 3'deoxy-3'-[(18) F]fluorothymidine ([(18) F]FLT) as a proliferation imaging tracer in humans: Correlation of [(18) F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometryin human lung tumours. Clin Cancer Res 2002; 8: 3315. (Pubitemid 35340704)
42. Yamamoto Y, Nishiyama Y, Ishikawa S, et al. Correlation of (18) FLT and (18) FDG uptake on PET with Ki-67 immunohistochemistry in non-small-lung cancer. Eur J Nucl Med Mol Imaging 2007; 34: 1610. 6. (Pubitemid 47476919)
43. 18F-FGD. J Nucl Med 2005: 945. (Pubitemid 43733508)
44. 18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging 2005; 32: 257. (Pubitemid 40562116)
45. 18F- fluorothymidine as a new marker for monitoring tumour response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003; 63: 3791. (Pubitemid 36793068)
46. 18F-fluorothymidine for monitoring of tumour response to radiotherapy and photodynamic therapy in mice. J Nucl Med 2004; 45: 1754. (Pubitemid 47618487)
47. Bading JR, Shields AF. Imaging of cell proliferation: Status and prospects. J Nucl Med 2008; 49 (Suppl 2) : 64S.
48. Nishii R, Volgin AY, Mawlawi O, et al. Evaluation of 2'- deoxy-2'-[18F]fluoro-5-methyl-1-beta-L:-arabinofuranosyluracil ([18F]-L:-FMAU) as a PET imaging agent for cellular proliferation: Comparison with [18F]-D:-FMAU and [18F]FLT. Euro J Nucl Med Mol Imaging 2008; 35: 990.
49. Bading JR, Shahinian AH, Vail A, et al. Pharmacokinetics of the thymidine analog 2'-fluoro-5-methyl-1-beta-D- arabinofuranosyluracil (FMAU) in tumor-bearing rats. Nucl Med Biol 2004; 31: 407. (Pubitemid 38490740)
50. Ramírez de Molina A, Rodríguez-González A, Gutiérrez R, et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and human colorectal cancers. Biochem Biophy Res Commun 2002; 296: 580.
51. 11C-choline as a PET biomarker for assessment of prostate cancer tumour models. Bioorg Med Chem 2004; 12: 2887. (Pubitemid 38622124)
52. 18F-fluorodeoxyglucose for positron emission tomography of androgen-dependent and androgenindependent prostate cancer. J Urol 2002; 168: 273. (Pubitemid 34640843)
53. 11C-acetate. J Nucl Med 2007; 48: 420. (Pubitemid 47604928)
54. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182.
55. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669. (Pubitemid 36749215)
56. Leung D, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306. (Pubitemid 20066716)
57. Nagengast WB, de Vries EG, Hospers GA, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 2007; 48: 1313. (Pubitemid 47242797)
58. Cai W, Chen K, Mohamedali KA, et al. PET of vascular endothelial growth factor receptor expression. J Nucl Med 2006; 47: 2048. (Pubitemid 47544993)
59. Huynh H, Chow PK, Palanisamy N, et al. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Hepatol 2008; 49: 52.
60. Cabebe E, Wakelee H. Role of antiangiogenesis agents in treating NSCLC: Focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol 2007; 8: 15.
61. Buie LW, Valgus J. Bevacizumab: A treatment option for recurrent glioblastoma multiforme. Ann Pharmacother 2008; 42: 1486.
62. Scott LJ. Bevacizumab: In first-line treatment of metastatic breast cancer. Ann Pharmacother 2008; 42: 1486;
63. Drugs 2007; 67: 1793.
64. Friedlander M, Brooks PC, Shaffer RW, et al. Definition of two angiogenic pathways by distinct av integrins. Science 1995; 270: 1500. (Pubitemid 3005294)
65. Horton MA. The avb3 integrin vitronectin receptor. Int J Biochem Cell Biol 1997; 29: 721.
66. Bello L, Francolini M, Marthyn P. avb3 and avb5 integrin expression in glioma periphery discussion 390. Neurosurgery 2001; 49: 380. (Pubitemid 32721066)
67. Kumar CC. Integrin avb3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targ 2003; 4: 123.
68. Friedlander M, Threefeld CL, Sugita M, et al. Involvement of integrin alpha v beta 3 and alpha v beta 5 in ocular neovascular disease. Proc Nat Acad Sci USA 1996; 93: 9764.
69. Jin H, Varner J. Integrins: Roles in cancer development and as treatment targets. Br J Cancer 2004; 90: 561. (Pubitemid 38297190)
70. 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy. J Nucl Med 2006; 47: 2000.
71. 18F-FRGD2. J Nucl Med 2006; 47: 113.
72. Tucker GC. av integrin inhibitors and cancer therapy. Curr Opin Investig Drugs 2003; 4: 722.
73. Dijkgraaf I, Kruijtzer JA, Liu S, et al. Improved targeting of the avb3 integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging 2007; 34: 267.
74. 111Inlabeled RGD peptide. Nucl Med Biol 2007; 34: 29. (Pubitemid 46038156)
75. 18F-galacto- RGD in cancer patients. J Nucl Med 2005; 46: 1333.
76. 68Ga-labeled c (RGDyK) -isothiocyanatobenzyl-1, 4, 7-triazacyclononane-1, 4, 7- triacetic acid and feasibility studies in mice. J Nucl Med 2008; 49: 830.
77. Hogsteen LJ, Marres HAM, van der Kogel AJ, Kaanders JHAM. The hypoxic tumour microenvironment, patient selection and hypoxia-modifying treatments. Clin Oncol 2007; 19: 385. (Pubitemid 47007426)
78. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379: 88. (Pubitemid 26008141)
79. 18FMISO) : A comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol 2003; 30: 317. (Pubitemid 36556247)
80. 18F]EF3: Improvement of the tumour-to-background ratio in a mouse tumour model. Eur J Nucl Med Mole Imaging 2007; 34: 1348. (Pubitemid 47312583)
81. 18F]EF3 uptake on an individual mouse tumour basis. Eur J Nucl Med Mol Imaging 2006; 33: 553.
82. 18F]FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging 2004; 31: 513. (Pubitemid 38461566)
83. 18F]Fluoromisonidazole positron emission tomography. Int J Onc 2007; 30: 873.
84. van Engeland M, Nieland LJ, Ramaekers FC, et al. Annexin V-affinity assay: A review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 1998; 31: 1. (Pubitemid 28050057)
85. van Heerde WL, de Groot PG, Reutelingsperger CP. The complexity of the phospholipid binding protein Annexin V. Thromb Haemost 1995; 73: 172.
86. 99mTc Rh-Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res 2002; 8: 2766.
87. Aloya R, Shirvan A, Grimberg H, et al. Molecular imaging of cell death in vivo by a novel small molecule probe. Apoptosis 2006; 11: 2089.
88. Cauchon N, Langlois R, Rousseau JA, et al. PET imaging of apoptosis with (64) Cu-labeled streptavidin following pretargeting of phosphatidylserine with biotinylated Annexin- V. Eur J Nucl Med Mol Imaging 2007; 34: 247. (Pubitemid 46147508)
89. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions. J Clin Oncol 2005; 23: 2556.
90. Saba NF, Khuri FR, Shin DM. Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer. Oncology 2006; 20: 153. (Pubitemid 46931063)
91. Halatsch ME, Schmidt U, Behnke-Mursch J, et al. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev 2006; 32: 74. (Pubitemid 43362229)
92. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002; 20: 1S.
93. 18F-gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging 2008; 35: 1089.
94. 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol 2006; 8: 262. (Pubitemid 44446020)
95. Velikyan I, Sundberg AL, Lindhe O, et al. Preparation and evaluation of (68) Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Medi 2005; 46: 1881. (Pubitemid 46196651)
96. Mintun MA, Welch MJ, Siegel BA. Breast cancer: PET imaging of estrogen receptors. Radiology 1988; 169: 45. (Pubitemid 18221696)
97. Fisher ER, Anderson S, Dean S. Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma. Cancer 2005; 103: 164. (Pubitemid 39665470)
98. Aliaga A, Rousseau JA, Ouellette R, et al. Breast cancer models to study the expression of estrogen receptors with small animal PET imaging. Nucl Med Biol 2004; 31: 761. (Pubitemid 38887758)